What is Crystal Pharmatech?
Established in 2010, Crystal Pharmatech operates as a technology-driven contract research organization specializing in the complex intersection of materials science and pharmaceutical development. The firm distinguishes itself through a highly integrated service model that encompasses API solid-state research, crystallization, preformulation, and formulation development. With a strategic international footprint, the company maintains sophisticated R&D centers across Suzhou, New Jersey, San Francisco, and Toronto. This global presence allows Crystal Pharmatech to provide seamless support for clinical supply and manufacturing, effectively positioning itself as an essential partner for biopharmaceutical companies seeking to optimize drug delivery and stability profiles.
The company's technical prowess in solid-state chemistry and formulation engineering serves as a primary differentiator in a market increasingly focused on precision medicine and complex molecule development. By streamlining the transition from laboratory-scale research to commercial-grade clinical supply, Crystal Pharmatech addresses critical bottlenecks in the drug development pipeline, ensuring that pharmaceutical innovators can navigate regulatory and technical hurdles with greater efficiency.
How much funding has Crystal Pharmatech raised?
Crystal Pharmatech has raised a total of $10M across 1 funding round:
Series A
$10M
Series A (2015): $10M with participation from Renren
Key Investors in Crystal Pharmatech
Renren
A Beijing-based investment entity with a historical focus on the internet and technology sectors, now diversifying its portfolio into strategic industrial and life science ventures.
What's next for Crystal Pharmatech?
With the recent influx of capital, Crystal Pharmatech is well-positioned to scale its specialized service offerings and expand its global R&D infrastructure. The strategic focus will likely center on enhancing its proprietary technology platforms to meet the growing demand for complex API development and advanced formulation techniques. As the CRO industry continues to consolidate, Crystal Pharmatech's ability to provide end-to-end solutions—from initial solid-state characterization to clinical supply—will be pivotal in capturing additional market share. Future growth initiatives are expected to prioritize the integration of digital tools into their research workflows, further cementing their reputation as a leader in high-tech pharmaceutical support services.
See full Crystal Pharmatech company page
